Genakumab

DRUG4 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Active Systemic Juvenile Idiopathic ArthritisAcute Gout ArthritisJuvenile Idiopathic ArthritisMalignant Solid Tumors

Phase 1

Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers

Changchun GeneScience Pharmaceutical Co., Ltd.Juvenile Idiopathic Arthritis

Start: 2019-04-22End: 2020-09-30Target: 40Updated: 2020-04-07

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.Malignant Solid Tumors

Start: 2022-06-07End: 2025-03-31Target: 120Updated: 2022-07-06

Phase 3

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

CompletedNCT05983445

Changchun GeneScience Pharmaceutical Co., Ltd.Acute Gout Arthritis

Start: 2023-01-11End: 2024-04-03Updated: 2024-12-18

Unknown Phase

To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

RecruitingNCT05925452

Changchun GeneScience Pharmaceutical Co., Ltd.Active Systemic Juvenile Idiopathic Arthritis

Start: 2023-12-01End: 2028-06-29Target: 290Updated: 2026-09-17

Related Papers

Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.

2026-05-19

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study.

2026-03-11

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Firsekibart, an Anti-interleukin-1β Monoclonal Antibody, in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

2025-07-251 citations